Statistics indicate that sufferers are far more likely to drop out of school, have few or no friends, underperform at work, engage in antisocial activities and smoke or use illegal drugs. It’s imperative that children with this disorder are quickly identified. There are a range of symptoms that should alert teachers and parents to this condition, the most obvious being the child’s inability to pay attention.
As proven by recently published clinical trials, eye q is the tried and tested unique fatty-acid formulation that has been shown to help children with ADHD to optimise their concentration, classroom performance and behaviour levels.
Dr Eduardo Barragan, an independent investigator, initiated a study demonstrating the efficacy and safety of eye q, methylphenidate (MPH) and a combined treatment in children with ADHD.
The results of an exploratory study suggest that the specific combination of eye q (tested in a year-long trial) is an effective, well-tolerated option for children with ADHD when used as monotherapy in the inattentive subtype. Adverse events were also numerically less frequent with eye q or MPH plus eye q than with MPH alone. These results were published in the Journal of Attention Disorders.
Eye q, produced by Arctic Healthcare, is available at leading pharmacies nationwide in four formulations: Baby, Liquid, Capsules and Strawberry-flavoured Chews.
For more information, please visit www.eyeqsa.co.za.
